Last reviewed · How we verify

NCT04346992

Prevalence Of Keratoconus Among Patients With Thyroid Gland Dysfunction

Completed Last updated 8 September 2022
What this trial tests

trial testing no intervention in Keratoconus in Thyroid Gland Dysfunction in 400 participants. Completed in 15 March 2022.

Timeline
12 April 2020
Primary endpoint
15 March 2022
15 March 2022

Quick facts

Lead sponsorFayoum University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date12 April 2020
Primary completion15 March 2022
Estimated completion15 March 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Fayoum University

Who can join

Adults 18 to 70, any sex, with Keratoconus in Thyroid Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hormonal imbalances are likely to affect the corneal metabolism and may be also associated with Keratoconus. Among the various endocrinologic dysfunctions assumed so far, thyroid gland dysfunction (TGD) (hypo- or hyperthyroidism; comprised as TGD) is frequently associated with eye diseases such as Graves disease

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other Fayoum University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04346992.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing